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Background: It has been recently postulated that not only the quantity but also quality of HDL play an important role in the progression and 
regression of atherosclerosis. Pitavastatin is a unique statin that possesses both LDL-decreasing and HDL-increasing effects. To clarify whether the 
HDL increased by pitavastatin exert functional anti-atherosclerotic properties, we examined the qualitative and quantitative changes of HDL during 
pitavastatin treatment.
methods: A total of 23 dyslipidemic patients were administered with pitavastatin for 4 weeks. Serum lipid profile, paraoxonase (PON1), platelet-
activating factor acetylhydolase (PAF-AH), and cholesterol efflux capacity of purified HDL fraction by polyethethylenglycol-precipitation and HDL were 
evaluated at baseline and after the pitavastatin treatment.
results: Administration of dyslipidmic patients with 2mg pitavastatin resulted in a 40% decrease in serum LDL-C levels (P<0.01) and a 9.5% 
increase in HDL-C levels (P<0.05). Cholesterol efflux capacity of purified HDL fraction was positively correlated with serum HDL-C levels, and 
pitavastatin-induced increase in HDL-C levels is concomitant with the increase in cholesterol efflux capacity of HDL. Activity of HDL-associated 
PON1 (paraoxonase and arylesterase) post-pitavastatin treatment was increased by 10% (P<0.05) and by 14% (P<0.05), respectively, while HDL-
associated PAF-AH activity was not affected by pitavastatin. Furthermore, the pitavastatin treatment increased size and content of phospholipids in 
HDL particles, which may enhance HDL efflux capacity.
conclusion: Besides decreasing serum LDL-C levels, pitavastatin elevates serum HDL-C levels and modulates the size, composition and levels of 
HDL-associated enzymes, but as a whole, increases HDL particles with preserved anti-atherosclerotic properties.
